Investigators sought to determine the long-term safety and efficacy of fremanezumab in patients with chronic migraine and comorbid moderate to severe depression.
All articles by M Tewar, MD
Mark Zimmerman, MD, discusses controversies related to categorizing severity and identifying optimal treatment of depression.
Latest News Your top articles for FridayFor More Personalized News
Haymarket Medical NetworkTop Picks
Continuing Medical Education (CME/CE) Courses